3Brain AG recently announced the development of a new technology that integrates microchips and artificial intelligence. The revolutionary duo has the potential to fundamentally alter how drug candidates are selected in the preclinical stage. This increases their chances of success.
Preclinical studies are deemed to be the most critical for identifying safety and efficacy concerns promptly. Despite numerous advancements in drug delivery, it frequently fails due to limited drawbacks in preclinical tests on animal models. Another significant disadvantage is that drugs that work successfully in animals often fail to work in humans.
To address the pervasive problems associated with drug delivery, new biotechnologies are being introduced. New biotechnologies that mimic and perform similarly to human stem cells are considered viable alternatives to animal models.
These structures are created using a combination of artificial intelligence and microchips and consist of cell culture and organoid assays that can be used as drug testbeds. These cell-based assays are transforming the process of drug development.
The Disruption of the Traditional: A Transition from the Traditional to the Biotechnological
Medical experts and physicians have expressed dissatisfaction with traditional drug delivery methods. Due to several limitations, conventional methods of drug delivery were unable to act across a wide bandwidth. Standard plastic multi-well plates are transformed into intelligent devices with multi-core processing power from a sustainability and cost perspective. These devices are programmable and can be updated regularly.
The ultimate goal is to accelerate the delivery of cures for diseases, thereby increasing readiness. This can be described as a significant and necessary disruption of the established paradigm while preserving cost-effectiveness and sustainability.